Novo Nordisk shares new health benefits of Wegovy

Novo Nordisk is reshaping how we view Wegovy, a medication originally known primarily for weight loss.

Recent data, including insights from the landmark SELECT trial, reveal that Wegovy offers significant health benefits that extend far beyond shedding pounds.

For patients with obesity and cardiovascular disease, the drug has been shown to reduce the risk of major events like heart attacks and strokes by 20%.

Beyond heart health, researchers are discovering that semaglutide—the active ingredient in Wegovy—may help manage various obesity-related comorbidities.

These benefits are likely tied to the drug’s ability to reduce systemic inflammation.

Wegovy is increasingly recognized not merely as a weight-loss tool, but as a comprehensive therapy for the interconnected health risks that accompany obesity.

This evolution marks a significant milestone in modern metabolic medicine.